A Petzold1, G Keir, A Kay, M Kerr, E J Thompson. 1. Department of Neuroimmunology, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. a.petzold@ion.ucl.ac.uk
Abstract
BACKGROUND: On the basis of preliminary evidence from patients with subarachnoid haemorrhage (SAH), axonal degeneration is thought to be an underestimated pathological feature. METHODS: A longitudinal study in 17 patients with aneurysmal SAH. Ventricular CSF was collected daily for up to 14 days. The neurofilament heavy chain(SMI35) (NfH(SMI35), a biomarker for axonal damage) was quantified using a standard ELISA (upper limit of normal 0.73 ng/ml). The primary outcome measure was the Glasgow Outcome Score (GOS) at 3 months. RESULTS: Of 148 samples from patients with SAH, pathologically high NfH levels in the CSF were found in 78 (52.7%) samples, compared with 20 (5%) of 416 samples from the reference population (p<0.0001). A pathological increase in NfH was observed in all patients with a bad outcome (GOS 1-3) compared with 8% of those with a good outcome (GOS 4-5, p<0.0001). This increase typically became significant 7 days after the haemorrhage (p<0.01). The result was confirmed by analysing the individual mean NfH concentrations in the CSF (3.45 v 0.37 ng/ml, p<0.01), and was reinforced by the inverse correlation of NfH in the CSF with the GOS (r = -0.65, p<0.01). Severity of injury was found to be correlated to NfH(SMI35) levels in the CSF (World Federation of Neurological Surgeons, r = 0.63, p<0.01 and Glasgow Coma Score, r = -0.61, p<0.01). CONCLUSION: Patients with SAH thus have secondary axonal degeneration, which may adversely affect their outcome.
BACKGROUND: On the basis of preliminary evidence from patients with subarachnoid haemorrhage (SAH), axonal degeneration is thought to be an underestimated pathological feature. METHODS: A longitudinal study in 17 patients with aneurysmalSAH. Ventricular CSF was collected daily for up to 14 days. The neurofilament heavy chain(SMI35) (NfH(SMI35), a biomarker for axonal damage) was quantified using a standard ELISA (upper limit of normal 0.73 ng/ml). The primary outcome measure was the Glasgow Outcome Score (GOS) at 3 months. RESULTS: Of 148 samples from patients with SAH, pathologically high NfH levels in the CSF were found in 78 (52.7%) samples, compared with 20 (5%) of 416 samples from the reference population (p<0.0001). A pathological increase in NfH was observed in all patients with a bad outcome (GOS 1-3) compared with 8% of those with a good outcome (GOS 4-5, p<0.0001). This increase typically became significant 7 days after the haemorrhage (p<0.01). The result was confirmed by analysing the individual mean NfH concentrations in the CSF (3.45 v 0.37 ng/ml, p<0.01), and was reinforced by the inverse correlation of NfH in the CSF with the GOS (r = -0.65, p<0.01). Severity of injury was found to be correlated to NfH(SMI35) levels in the CSF (World Federation of Neurological Surgeons, r = 0.63, p<0.01 and Glasgow Coma Score, r = -0.61, p<0.01). CONCLUSION:Patients with SAH thus have secondary axonal degeneration, which may adversely affect their outcome.
Authors: Mohamed Ouardouz; Maria A Nikolaeva; Elaine Coderre; Gerald W Zamponi; John E McRory; Bruce D Trapp; Xinghua Yin; Weili Wang; John Woulfe; Peter K Stys Journal: Neuron Date: 2003-09-25 Impact factor: 17.173
Authors: Ming C Liu; Linnet Akinyi; Dancia Scharf; Jixiang Mo; Stephen F Larner; Uwe Muller; Monika W Oli; Wenrong Zheng; Firas Kobeissy; Linda Papa; Xi-Chun Lu; Jitendra R Dave; Frank C Tortella; Ronald L Hayes; Kevin K W Wang Journal: Eur J Neurosci Date: 2010-02 Impact factor: 3.386
Authors: E R Zanier; D Refai; G J Zipfel; T Zoerle; L Longhi; T J Esparza; M L Spinner; R J Bateman; D L Brody; N Stocchetti Journal: J Neurol Neurosurg Psychiatry Date: 2010-06-22 Impact factor: 10.154
Authors: Michael Moussouttas; Thanh T Huynh; John Khoury; Edwin W Lai; Keith Dombrowski; Scott Pello; Karel Pacak Journal: Cerebrovasc Dis Date: 2012-01-05 Impact factor: 2.762
Authors: Gian Marco De Marchis; Christopher G Filippi; Xiaotao Guo; Deborah Pugin; Christopher D Gaffney; Neha S Dangayach; Sureerat Suwatcharangkoon; M Cristina Falo; J Michael Schmidt; Sachin Agarwal; E Sander Connolly; Jan Claassen; Binsheng Zhao; Stephan A Mayer Journal: Neurocrit Care Date: 2015-02 Impact factor: 3.210
Authors: Caron M Hong; Cigdem Tosun; David B Kurland; Volodymyr Gerzanich; David Schreibman; J Marc Simard Journal: Biomarkers Date: 2014-02-05 Impact factor: 2.658
Authors: Christian Burrell; Nicole E Avalon; Jason Siegel; Michael Pizzi; Tumpa Dutta; M Cristine Charlesworth; William D Freeman Journal: Expert Rev Neurother Date: 2016-07-11 Impact factor: 4.618